Novel Prognostic Markers in Renal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by Royal Marsden NHS Foundation Trust.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01002937
First received: October 27, 2009
Last updated: NA
Last verified: October 2009
History: No changes posted
  Purpose

The purpose of this project is to analyze tumour tissue from a group of subjects with renal cell carcinoma, who have been treated at the Royal Marsden Hospital.


Condition
Renal Cell Carcinoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Novel Prognostic Markers in Renal Cancer: a Protocol for the Analysis of Paraffin Embedded Tumour Samples

Resource links provided by NLM:


Further study details as provided by Royal Marsden NHS Foundation Trust:

Primary Outcome Measures:
  • The profiling of the expression of signal transduction biomarkers, gene expression, gene copy numbers and effect of mutations of the VHL gene in renal cancer and their relationship to clinical outcomes. [ Designated as safety issue: No ]

Estimated Enrollment: 500
Study Start Date: December 2008
Estimated Study Completion Date: March 2011
Estimated Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Tumour tissue, renal cell carcinoma
> 2mm x 2mm of tumour tissue obtained from paraffin blocks taken from biopsies or nephrectomy specimens.

Detailed Description:

Renal cancers have different clinical outcomes. The principal research objective is to study tumour tissue from renal cancer patients and try and understand why some cancers progress more rapidly than others. Further, another key aim of this study is to try and understand why some patients respond to treatment and others do not.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Tumour tissue from subjects with renal cell carcinoma, who have been treated at the Royal Marsden Hospital

Criteria

Inclusion Criteria:

  • The presence of histologically proven renal cell cancer
  • The availability of paraffin embedded tissue
  • Informed consent needed for tissue taken after January 2006 (date of enforcement of human tissue act)

Exclusion Criteria:

  • Absence of histological tissue
  • Absence of consent to study tissue after January 2006
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01002937

Contacts
Contact: Professor Martin Gore 02078082198 martin.gore@rmh.nhs.uk

Locations
United Kingdom
Royal Marsden NHS Foundation Trust Recruiting
Sutton, Surrey, United Kingdom, SM2 5PT
Sponsors and Collaborators
Royal Marsden NHS Foundation Trust
Investigators
Principal Investigator: Professor Martin Gore Royal Marsden NHS Foundation Trust
  More Information

No publications provided

Responsible Party: Professor Martin Gore, Royal Marsden NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT01002937     History of Changes
Other Study ID Numbers: CCR3076
Study First Received: October 27, 2009
Last Updated: October 27, 2009
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Royal Marsden NHS Foundation Trust:
Biomarkers
Prognosis response to treatment
Renal cancer

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Renal Cell
Kidney Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on September 14, 2014